As we roll into November we are also getting into upper respiratory illnesses season.RSV has been of great concern the last few years, with October and November
The Centers for Disease Control and Prevention is advising providers to prioritize 100 mg doses of nirsevimab, a monoclonal antibody FDA-approved to prevent respiratory syncytial virus (RSV), for infants at the highest risk of severe RSV disease.
According to a recent news release from St. Luke's, during the fall and winter seasons, the spread of respiratory viruses increases, including flu, COVID-19 and